文献速递中枢神经肿瘤放疗放疗物理与技术

放射诱发胶质瘤患者的治疗结局评估及再程放疗的作用

Assessment of therapeutic outcome and role of reirradiation in patients with radiation-induced glioma.
PubMed 文献 · Radiat Oncol · 2022-05-03

该回顾性研究纳入2001—2021年符合Cahan标准的11例放射诱发高级别胶质瘤患者,分析IDH1/2突变状态及治疗结局。再程放疗联合化疗组(n=5)的中位无进展生存期倾向于长于单纯化疗组(n=6)(17.0 vs 8.1个月),但中位总生存期相近(29.6 vs 27.4个月)。作者认为再程放疗联合化疗似乎可行且结局良好。

要点

  • 放射诱发胶质瘤可在原发肿瘤放疗成功后超过20年发生,中位间隔17年(范围9—30年)。
  • 再程放疗联合化疗组中位无进展生存期17.0个月,单纯化疗组8.1个月,但总生存期相近。
  • 原发为胶质瘤时,IDH1/2突变状态有助于确立放射诱发胶质瘤的诊断。

核心结论

  • 放射诱发胶质瘤可在成功放疗原发疾病后超过20年发生,癌症幸存者应被告知该长期风险及及时进行神经影像学评估的必要性。
  • 再程放疗联合化疗似乎可行且结局良好。
  • 当原发肿瘤为胶质瘤时,确定IDH1/2突变状态有助于确立放射诱发胶质瘤诊断。

研究设计与样本

  • 回顾性分析2001—2021年数据库中符合Cahan放射诱发胶质瘤标准的11例高级别胶质瘤患者的临床特征与治疗结局。
  • IDH1/2突变通过Sanger测序和/或焦磷酸测序分析。

主要发现

  • 放射诱发胶质瘤包括IDH1/2野生型胶质母细胞瘤7例、非特指型胶质母细胞瘤2例、IDH1/2野生型间变性星形细胞瘤1例及非特指型间变性星形细胞瘤1例。
  • 原发疾病至放射诱发胶质瘤诊断的中位间隔为17年(范围9—30年)。
  • 全部患者接受肿瘤切除或活检,术后5例接受再程放疗联合化疗,6例接受单纯化疗。
  • 中位无进展生存期与生存期分别为11.3个月和28.3个月。
  • 再程放疗联合化疗组(n=5)中位无进展生存期倾向于长于单纯化疗组(n=6)(17.0 vs 8.1个月),但中位生存期相近(29.6 vs 27.4个月)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: We sought to clarify the optimal follow-up, therapeutic strategy, especially the role of reirradiation, and the diagnostic impact of isocitrate dehydrogenase (IDH) 1 and 2 mutation status in patients with radiation-induced glioma (RIG). METHODS: We retrospectively reviewed the clinical characteristics and treatment outcomes of 11 patients with high-grade glioma who satisfied Cahan's criteria for RIG in our database during 2001-2021. IDH 1/2 mutations were analyzed by Sanger sequencing and/or pyrosequencing. RESULTS: The RIGs included glioblastoma with IDH 1/2 wild-type (n = 7), glioblastoma not otherwise specified (n = 2), anaplastic astrocytoma with IDH1/2 wild-type (n = 1), and anaplastic astrocytoma not otherwise specified (n = 1). The median period from primary disease and RIG diagnosis was 17 years (range: 9-30 years). All patients underwent tumor removal or biopsy, 5 patients postoperatively received reirradiation combined with chemotherapy, and 6 patients were treated with chemotherapy alone. The median progression-free and survival times were 11.3 and 28.3 months. The median progression-free survival time of patients treated with reirradiation and chemotherapy (n = 5) tended to be longer than that of patients that received chemotherapy alone (n = 6) (17.0 vs 8.1 months). However, the median survival time was similar (29.6 vs 27.4 months). Local recurrence was observed in 5 patients treated with chemotherapy alone, whereas in 2 patients among 4 patients treated with reirradiation and chemotherapy. None of the patients developed radiation necrosis. In one case, the primary tumor was diffuse astrocytoma with IDH2 mutant, and the secondary tumor was glioblastoma with IDH 1/2 wild-type. Based on the difference of IDH2 mutation status, the secondary tumor with IDH 1/2 wild-type was diagnosed as a de novo tumor that was related to the previous radiation therapy. CONCLUSIONS: RIG can occur beyond 20 years after successfully treating the primary disease using radiotherapy; thus, cancer survivors should be informed of the long-term risk of developing RIG and the need for timely neuroimaging evaluation. Reirradiation combined with chemotherapy appears to be feasible and has favorable outcomes. Determining the IDH1/2 mutational status is useful to establish RIG diagnosis when the primary tumor is glioma.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Ohno M, Miyakita Y, Takahashi M, et al. Assessment of therapeutic outcome and role of reirradiation in patients with radiation-induced glioma. Radiat Oncol. 2022. PMID: 35505351. doi:10.1186/s13014-022-02054-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。